Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its cancer-drug pipeline through the acquisition of U.K.-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.
📍 The outcome
Novartis agreed to acquire U.K. cancer biotech Myricx Bio in a deal valued at up to $1.5 billion. The agreement included an upfront payment of $1.1 billion to expand Novartis's ADC pipeline.
Epilogue added 42d ago, after coverage quieted.
Who reported it (7)
- Four major biotech updates to catch up on STAT · 45d ago
- Novartis acquires U.K. cancer biotech Myricx Bio for $1.5 billion qz.com · 45d ago
- Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis Business Wire · 45d ago
- Novartis to buy UK biotech Myricx Bio in $1.5bn deal Financial Times · 45d ago
- Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline Fierce Biotech · 45d ago
- Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion Bloomberg.com · 45d ago
- Novartis to Buy Myricx Bio for Up to $1.5 Billion WSJ · 45d ago broke it first
Where it stands
Novartis has agreed to acquire Myricx Bio, a cancer biotech company based in the United Kingdom. The deal is valued at up to $1.5 billion, with Fierce Biotech reporting an upfront payment of $1.1 billion.
Coverage from Bloomberg, the Wall Street Journal, and the Financial Times emphasizes the deal's total valuation. Quartz and Business Wire identify the target as a U.K. biotech, while Fierce Biotech specifies that the move is intended to expand Novartis's antibody-drug conjugate (ADC) pipeline.
Further developments will likely focus on the integration of Myricx Bio into Novartis's oncology operations and the progression of the ADC pipeline.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 43d ago.
Answered
How much is Novartis paying for Myricx Bio?
The deal is valued at up to $1.5 billion, with $1.1 billion being paid upfront.
What is the primary goal of this acquisition?
According to Fierce Biotech, Novartis intends to use the acquisition to expand its ADC pipeline.
Where is Myricx Bio located?
Myricx Bio is a biotechnology firm based in the United Kingdom.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
The Surprising Reason This Biotech Plummeted 69%
EyePoint Pharmaceuticals shares cratered following a late-stage trial setback for its flagship eye disease drug.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
CRISPR makes prostate cancer vulnerable to immunotherapy
New CRISPR gene-editing research indicates a method to improve the immune system's ability to detect and target prostate cancer tumors.
Colorectal cancer is on the rise — and often overlooked
Medical experts and patient accounts highlight an increasing prevalence of early-onset colorectal cancer and the risks associated with missed symptoms.
The 'Surprisingly Soft' Unit That Caused Danaher To Plummet
Danaher shares slide despite second-quarter earnings and revenue beats, driven by softness in its biotech unit.
Creatine supplements may help halt cancer growth, study suggests
Scientific research into the impact of creatine supplementation on cancer development is sparking conflicting reports regarding its potential risks and benefits.